Every year, you get the same notification from your PBM: “Here are your formulary changes and here is the member disruption.” That’s all. Most plan sponsors absorb the changes, notify their members, and move on. What they don’t get is the financial analysis behind why those decisions were made: not the net cost impact, not … Waiting for Your PBM to Tell You What Changed Isn’t a Strategy
PBM reform is often framed as a policy story. But for health plans and payers, it’s really a stress test: can their pharmacy strategy withstand a market where pharmacy benefit structures are becoming easier to see, question, and connect back to plan performance? As new federal requirements, enforcement activity and state-level regulation put more pressure … PBM Reform Is Exposing the Limits of Legacy Pharmacy Strategy for Payers
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. Indication YUVIWEL (navepegritide) is FDA approved to increase linear growth in pediatric patients aged 2 years and older with achondroplasia and … Rx Insights from March ’26
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. IndicationYUVEZZI (carbachol and brimonidine tartrate) is the first and only preservative-free dual-agent ophthalmic drop approved for the treatment of presbyopia in adults. … Rx Insights from February ’26
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. Indication NEREUS (tradipitant) is a substance P/neurokinin-1 (NK-1) receptor antagonist indicated for the prevention of motion-induced vomiting in adults. Dosage and … RX Insights from January ’26
The future of pharmacy benefits is moving toward greater transparency, and that’s good news for employers, members, and the partners who support them. The FTC’s recent settlement and regulatory actions are raising expectations around reporting, visibility, and accountability across the drug benefit ecosystem. These changes will give employers clearer insight into drug level economics and … Pharmacy Benefits Transparency Isn’t the Future. It’s the Foundation.
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. IndicationARMLUPEG (pegfilgrastim-unne) is an FDA-approved biosimilar to Neulasta (pegfilgrastim) indicated to reduce the risk of infection, as manifested by febrile neutropenia, in … RX Insights from December ’25
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. KYGEVVI Indication KYGEVVI is approved by the FDA for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric … Rx Insights from November ’25
Qlare™ Data Assistant coming soon to ExpionIQ®
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. KEYTRUDA QLEX Indication KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa) is approved for the treatment of 38 indications, including melanoma, non–small cell … Rx Insights from October ’25
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. WAYRILZ Indication WAYRILZ (rilzabrutinib) is a kinase inhibitor approved by the FDA on August 29, 2025, for the treatment of adults … Rx Insights from September ’25
